Loading...
01/11 03:34
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call reflects a mixed sentiment. While the company reports decreased R&D and SG&A expenses, an increase in interest expense and a significant net loss raise concerns. The Q&A highlights management's optimism about future trials, yet lacks specifics on enrollment and liquidity strategies. The positive outlook on new data readouts and potential market opportunities is tempered by financial challenges. These mixed signals suggest a neutral impact on stock price, with no strong catalysts for a significant move in either direction.
Total revenue for Q2 2025 $37.9 million, a decrease from $42.8 million in Q2 2024. The decline was primarily due to $6 million of nonrecurring license-related revenue recognized in Q2 2024.
U.S. XPOVIO net product revenue for Q2 2025 $29.7 million, an increase from $28 million in Q2 2024. The increase was attributed to consistent demand and a reduction in gross-to-net provisions.
Gross-to-net provisions for XPOVIO in Q2 2025 26.8%, down from 45% in Q1 2025 and 29.3% in Q2 2024. The decline was driven by mix and lower 340B discounts.
R&D expenses for Q2 2025 $32.8 million, a 15% decrease from $38.4 million in Q2 2024. The reduction was due to lower headcount, contractor costs, and clinical trial expenses.
SG&A expenses for Q2 2025 $28.5 million, an 8% decrease from $31.1 million in Q2 2024. The decrease was due to cost reduction initiatives.
Interest expense for Q2 2025 $11.2 million, an increase from $8.9 million in Q2 2024. The increase was due to refinancing in Q2 2024, which raised interest expense.
Royalty revenue for Q2 2025 $1.6 million, a 28% increase from Q2 2024. The increase was due to higher global demand for XPOVIO and NEXPOVIO.
Net loss for Q2 2025 $37.3 million or $4.32 per share. This includes $11.2 million in interest expense and $2 million in noncash losses from remeasurement of derivatives and warrants.
Net loss from operations for Q2 2025 $24.5 million, reflecting the performance of the core business.
Cash, cash equivalents, restricted cash, and investments as of Q2 2025 $52 million, a decrease from $109.1 million as of December 31, 2024. The decrease was due to operational expenses and debt obligations.
Phase III SENTRY trial: Enrollment for the Phase III SENTRY trial in JAK-naive myelofibrosis is expected to close this week. The trial aims to redefine the standard of care with selinexor plus ruxolitinib, targeting a $1 billion annual revenue potential in the U.S. alone.
Endometrial cancer trial: Enrollment in the export EC042 trial for p53 wild-type endometrial cancer is progressing steadily, with top-line data expected in mid-2026.
Multiple myeloma trial: The Phase III EMN29 SPd trial aims to demonstrate an all-oral triplet treatment option for multiple myeloma, with top-line data expected in the first half of 2026.
Global expansion: Selinexor is now approved in 50 countries, contributing to a 28% increase in royalty revenue to $1.6 million in Q2 2025.
Revenue performance: XPOVIO net product revenue was $29.7 million in Q2 2025, up 6% year-over-year. Full-year 2025 revenue guidance is $140-$155 million.
Cost optimization: R&D and SG&A expenses decreased by 15% and 8% respectively, due to workforce reductions and cost-saving initiatives.
Liquidity management: The company is addressing near-term debt maturity in October 2025 and exploring financing and strategic alternatives to enhance liquidity.
Financial Constraints and Debt Maturity: The company is operating under financial constraints with a near-term debt maturity in October 2025. This creates liquidity challenges and necessitates active engagement with lenders and advisers to enhance liquidity and maximize value.
Market Competition: The multiple myeloma market is highly competitive and becoming more so each year, which could impact the company's ability to maintain or grow its market share for XPOVIO.
Enrollment Challenges in Clinical Trials: Enrollment in the Phase II SENTRY 2 trial has been slower than anticipated, partly due to prioritization of the Phase III SENTRY trial and the limited patient population with specific eligibility criteria.
Regulatory and Clinical Trial Risks: The success of the company's strategic objectives heavily depends on the outcomes of ongoing Phase III clinical trials in myelofibrosis and endometrial cancer. Any unfavorable results could significantly impact the company's future prospects.
Revenue Decline and Financial Performance: Total revenue for Q2 2025 declined compared to Q2 2024, primarily due to nonrecurring license-related revenue in the prior year. This decline, coupled with increased interest expenses, highlights financial pressures.
Operational Cost Management: The company has implemented cost reduction initiatives, including a 20% workforce reduction, to manage expenses. However, these measures may impact operational efficiency and employee morale.
Supply Chain and Manufacturing Risks: The company faces potential risks related to the supply chain and manufacturing processes, which could affect the timely delivery of products and clinical trial materials.
Dependence on Key Products: The company's financial health is heavily reliant on the success of XPOVIO and its potential approval for new indications. Any setbacks in these areas could adversely affect revenue and growth.
Phase III SENTRY trial in myelofibrosis: The company expects to close new patient screening this week and anticipates top-line data in March 2026. The trial aims to redefine the standard of care for myelofibrosis patients with a potential peak revenue of $1 billion annually in the U.S. alone.
Phase III export EC042 trial in endometrial cancer: Top-line data is expected in mid-2026. The trial targets p53 wild-type and MMR-proficient tumors, representing approximately 50% of advanced or recurrent endometrial cancer cases.
Phase III EMN29 SPd trial in multiple myeloma: Top-line data is expected in the first half of 2026. The trial aims to demonstrate the potential of an all-oral triplet treatment option for multiple myeloma patients.
Revenue guidance for 2025: The company expects total revenue of $140 million to $155 million, with U.S. XPOVIO net product revenue projected at $110 million to $120 million.
Cost reduction initiatives: A 20% workforce reduction is expected to lower annual spending by approximately $13 million starting in 2026.
Liquidity and financing: The company is working with advisers to explore financing and strategic alternatives to address liquidity and maximize value, with current liquidity expected to fund operations into January 2026.
The selected topic was not discussed during the call.
The earnings call presents a mixed outlook. While financial performance shows improvements in cost management and revenue growth, the company's guidance and liquidity concerns raise uncertainties. The Q&A section highlights potential growth in myelofibrosis treatment but lacks clarity on financing and market positioning. The absence of a strong catalyst like a new partnership or record revenue tempers expectations, resulting in a neutral sentiment.
The earnings call reflects a mixed sentiment. While the company reports decreased R&D and SG&A expenses, an increase in interest expense and a significant net loss raise concerns. The Q&A highlights management's optimism about future trials, yet lacks specifics on enrollment and liquidity strategies. The positive outlook on new data readouts and potential market opportunities is tempered by financial challenges. These mixed signals suggest a neutral impact on stock price, with no strong catalysts for a significant move in either direction.
The earnings call presents a concerning picture with declining revenues, increased product returns, and cash flow risks. Despite passing a futility analysis, clinical trials face enrollment challenges. The lack of a shareholder return plan adds to the negative sentiment. While there is some growth in multiple myeloma, competitive pressures and supply chain issues pose risks. Management's vague responses on cash runway and future risks further contribute to uncertainty. Overall, the sentiment leans negative due to financial instability and competitive market pressures.
The earnings call reveals mixed financial performance with a slight revenue increase but declining cash reserves. Regulatory risks, competitive pressures, and supply chain challenges pose significant threats. The Q&A section indicates some positive clinical trial progress but lacks clarity on key metrics. Guidance remains unchanged, and no new partnerships were announced. These factors, combined with the absence of strong catalysts, suggest a negative stock price movement in the short term, particularly with financial stability concerns and competitive pressures in key markets.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
